These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

576 related items for PubMed ID: 23666231

  • 1. Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
    Casey MJ, Bewtra C, Lynch HT, Snyder C, Stacy M, Watson P.
    Fam Cancer; 2013 Dec; 12(4):719-40. PubMed ID: 23666231
    [Abstract] [Full Text] [Related]

  • 2. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
    Casey MJ, Bewtra C.
    Fam Cancer; 2004 Dec; 3(3-4):265-81. PubMed ID: 15516851
    [Abstract] [Full Text] [Related]

  • 3. Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds: report from the Creighton University Hereditary Cancer Registry with review of the implications.
    Casey MJ, Bewtra C, Lynch HT, Snyder CL, Stacey M.
    Int J Gynecol Cancer; 2015 May; 25(4):650-6. PubMed ID: 25756400
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
    Chui MH, Ryan P, Radigan J, Ferguson SE, Pollett A, Aronson M, Semotiuk K, Holter S, Sy K, Kwon JS, Soma A, Singh N, Gallinger S, Shaw P, Arseneau J, Foulkes WD, Gilks CB, Clarke BA.
    Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
    [Abstract] [Full Text] [Related]

  • 6. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
    Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, van't Veer LJ.
    Br J Cancer; 2004 Apr 19; 90(8):1492-7. PubMed ID: 15083174
    [Abstract] [Full Text] [Related]

  • 7. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
    Piek JM, Torrenga B, Hermsen B, Verheijen RH, Zweemer RP, Gille JJ, Kenemans P, van Diest PJ, Menko FH.
    Fam Cancer; 2003 Apr 19; 2(2):73-8. PubMed ID: 14574155
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE, O'Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH, Reidy DL, Epstein AS, Lincoln A, Saldia A, Jacobs LM, Rau-Murthy R, Zhang L, Kurtz RC, Saltz L, Offit K, Robson ME, Stadler ZK.
    Cancer; 2015 Dec 15; 121(24):4382-8. PubMed ID: 26440929
    [Abstract] [Full Text] [Related]

  • 12. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.
    Yates MS, Meyer LA, Deavers MT, Daniels MS, Keeler ER, Mok SC, Gershenson DM, Lu KH.
    Cancer Prev Res (Phila); 2011 Mar 15; 4(3):463-70. PubMed ID: 21278312
    [Abstract] [Full Text] [Related]

  • 13. Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.
    Hodan R, Kingham K, Cotter K, Folkins AK, Kurian AW, Ford JM, Longacre T.
    Cancer Med; 2021 Feb 15; 10(3):1012-1017. PubMed ID: 33369189
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.
    Sakamoto I, Hirotsu Y, Nakagomi H, Ouchi H, Ikegami A, Teramoto K, Amemiya K, Mochizuki H, Omata M.
    Cancer; 2016 Jan 01; 122(1):84-90. PubMed ID: 26439132
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT, Watson P.
    Gynecol Oncol; 2000 Sep 01; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
    Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA, Hereditary Ovarian Cancer Clinical Study Group.
    JAMA; 2006 Jul 12; 296(2):185-92. PubMed ID: 16835424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.